



May 26, 2016

Genomic Health Announces Presentation of Seven Oncotype DX® Studies at the 2016 American Society of Clinical Oncology Annual Meeting, Including Additional Prospective Outcomes Analysis

Presentations in Breast and Prostate Cancers Underscore Genomic Health's Industry-leading Commitment to Help Physicians and Patients Optimize Cancer Treatment Decisions

REDWOOD CITY, Calif., May 26, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from seven Oncotype DX® studies at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place June 3-7 at McCormick Place in Chicago. The results will include:

- | Four sub-analyses from the large population-based observational study based on the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute (NCI). Highlights include two independent presentations by the SEER-NCI investigators revealing significant disparities in the use of Oncotype DX in patients with early-stage invasive breast cancer. The primary SEER Registry study results, presented at the [CTRC-AACR San Antonio Breast Cancer Symposium \(SABCS\) in December 2015](#), demonstrated that Oncotype DX accurately predicts prospective patient outcomes in more than 42,000 patients, including those with node-negative and node-positive breast cancer.
- | An oral presentation on the clinical use of the Oncotype DX Breast Recurrence Score™ and patient experiences in invasive breast cancer, led by investigators at the University of Michigan;
- | Five-year clinical outcomes results from the prospective Phase III PlanB trial, one of the largest contemporary adjuvant breast cancer trials in Europe, conducted by the West German Study Group (WSG); and
- | A study of the Oncotype DX Genomic Prostate Score in men with surgically treated intermediate- and high-risk prostate cancer.

"Results from the latest breast and prostate cancer studies highlight the important impact of Oncotype DX in changing the treatment paradigm for hundreds of cancer patients every day," said [Steven Shak, M.D.](#), chief scientific officer, Genomic Health. "The breadth and strength of evidence for the clinical utility of Oncotype DX continue to be uniquely recognized by leading authorities in cancer. For example, the National Comprehensive Cancer Network (NCCN), in its updated [breast cancer guidelines](#) regarding node-negative and node-positive patients, specifically named Oncotype DX as the 'best validated' test for chemotherapy prediction."

The ASCO abstracts are now available at <http://abstracts.asco.org/>. Following are details for each presentation (all times are in Central Daylight Time):

Saturday, June 4

- | **Abstract:** 6575
Poster Session: Health Services Research and Quality of Care
Title: "Breast cancer specific survival in patients with node positive hormone receptor positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database"
Authors: Megan Roberts, Ph.D.
Location: Hall A
Time: 1-4:30 p.m.
- | **Abstract:** 5049
Poster Session: Genitourinary (Prostate Cancer)
Title: "A 17-gene genomic prostate score (GPS) as a predictor of biochemical (BCR) and clinical recurrence (CR) in men with surgically treated intermediate- and high-risk prostate cancer (PCa)"
Authors: Eric A. Klein, M.D.
Location: Hall A
Time: 1-4:30 p.m.
- | **Abstract:** 6552
Poster Session: Health Services Research and Quality of Care

Title: "Compliance with guidelines and factors associated with ordering the 21-gene breast cancer assay"

Author: Valentina I. Petkov, M.D., M.P.H.

Location: Hall A

Time: 1-4:30 p.m.

| **Abstract:** 6553

Poster Session: Health Services Research and Quality of Care

Title: "Dissemination of 21-gene assay testing among female breast cancer patients in the US"

Authors: Kathleen Cronin, Ph.D., M.P.H.

Location: Hall A

Time: 1-4:30 p.m.

Sunday, June 5

| **Abstract:** 556

Poster Session: Breast Cancer - HER2/ER

Title: "Prognostic impact of 21-Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2- early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial"

Authors: Oleg Gluz, M.D.

Location: Hall A

Time: 8-11:30 a.m.

| **Abstract:** 574

Poster Session: Breast Cancer - HER2/ER

Title: "Outcome disparities by age and 21-gene recurrence score (RS) in hormone receptor positive (HR+) breast cancer (BC)"

Authors: Valentina I. Petkov, M.D., M.P.H.

Location: Hall A

Time: 8-11:30 a.m.

Monday, June 6

| **Abstract:** 6501

Oral Session: Health Services Research and Quality of Care

Title: "Clinical use of the 21-gene assay and patient experiences in early-stage breast cancer"

Author: Steven J. Katz, M.D., M.P.H.

Location: S100a

Session Time: 9:45 a.m.-12:45 p.m.

Oral Presentation Time: 9:57-10:09 a.m.

About Oncotype DX[®]

The Oncotype DX[®] portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. With more than 600,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about [Oncotype DX tests](#), visit www.OncotypeDX.com, www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.

About Genomic Health

[Genomic Health](#), Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of cancer, one of the greatest issues in healthcare today. With its Oncotype IQ[™] Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 600,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid and tissue-based tests. The company is based in [Redwood City](#), California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: [@GenomicHealth](#), [Facebook](#), [YouTube](#) and [LinkedIn](#).

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties are set forth in our filings with the Securities and Exchange Commission, including in our quarterly report on Form 10-Q for the

quarter ended March 31, 2016. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, DCIS Score, Oncotype SEQ, and Oncotype IQ are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

GHDX-B



Logo - <http://photos.prnewswire.com/prnh/20130425/SF01493LOGO>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/genomic-health-announces-presentation-of-seven-oncotype-dx-studies-at-the-2016-american-society-of-clinical-oncology-annual-meeting-including-additional-prospective-outcomes-analysis-300275292.html>

SOURCE Genomic Health, Inc.

News Provided by Acquire Media